We are live on ! Find out more
ABOS icon

Acumen Pharmaceuticals
ABOS

71 hedge funds and large institutions have $75.2M invested in Acumen Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 22 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

23% more capital invested

Capital invested by funds: $61.1M → $75.2M (+$14.1M)

3% more funds holding

Funds holding: 69 → 71 (+2)

0.12% less ownership

Funds ownership: 58.99% → 58.87% (-0.12%)

41% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 22

Holders
71
Holders Change
+2
Holders Change %
+2.9%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
13
Reduced
22
Closed
8
Calls
$70K
Puts
–
Net Calls
+$70K
Net Calls Change
+$25K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$315K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$149K
3
PFS
Prospera Financial Services
Texas
+$99.2K
4
XT
XTX Topco
Cayman Islands
+$98.3K
5
QC
Quadrature Capital
United Kingdom
+$97.3K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$320K
2
Citadel Advisors
Citadel Advisors
Florida
-$295K
3
Jane Street
Jane Street
New York
-$129K
4
Two Sigma Investments
Two Sigma Investments
New York
-$112K
5
Goldman Sachs
Goldman Sachs
New York
-$58.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$31.5M – – –
SCV
2
Sands Capital Ventures
Virginia
$7.21M – – –
Franklin Resources
3
Franklin Resources
California
$4.86M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$4.28M -$3.63K -1,828 -0.1%
Vanguard Group
5
Vanguard Group
Pennsylvania
$3.49M +$4.56K +2,300 +0.1%
KIA
6
Knollwood Investment Advisory
Maryland
$3.44M – – –
Alyeska Investment Group
7
Alyeska Investment Group
Illinois
$1.98M – – –
ACM
8
ADAR1 Capital Management
Texas
$1.88M – – –
LCM
9
Laurion Capital Management
New York
$1.83M – – –
Pathstone Holdings
10
Pathstone Holdings
New Jersey
$1.81M – – –
Hudson Bay Capital Management
11
Hudson Bay Capital Management
Connecticut
$1.53M -$8 -4 -0%
Millennium Management
12
Millennium Management
New York
$1.23M -$34.9K -17,573 -3%
Renaissance Technologies
13
Renaissance Technologies
New York
$893K -$320K -161,192 -28%
Two Sigma Advisers
14
Two Sigma Advisers
New York
$890K -$3.57K -1,800 -0.4%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$866K +$22.7K +11,428 +3%
SG Americas Securities
16
SG Americas Securities
New York
$846K -$5.62K -2,831 -0.7%
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$787K +$315K +158,758 +74%
Citadel Advisors
18
Citadel Advisors
Florida
$729K -$295K -148,825 -30%
IC
19
Ikarian Capital
Texas
$537K -$22.7K -11,457 -4%
Bank of America
20
Bank of America
North Carolina
$507K +$52.4K +26,423 +12%
BCM
21
Bridgeway Capital Management
Texas
$359K -$39.7K -20,000 -11%
BlackRock
22
BlackRock
New York
$358K -$10.3K -5,185 -3%
Morgan Stanley
23
Morgan Stanley
New York
$352K +$34.7K +17,504 +12%
Acadian Asset Management
24
Acadian Asset Management
Massachusetts
$320K +$149K +74,860 +96%
Two Sigma Investments
25
Two Sigma Investments
New York
$302K -$112K -56,225 -28%
1
2 3 4

ABOS Hedge Fund Activity: Q4 2025 in Review

71 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q4 2025, worth a combined $75.2M — up 23% from $61.1M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ABOS positions and 8 closed out — a net gain of 4 holders — while 13 added to existing stakes and 22 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $315K. The largest seller was Renaissance Technologies, cutting an estimated $320K.

  • 71 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q4 2025, up from 69 in Q3 2025.
  • Funds reported $75.2M of Acumen Pharmaceuticals stock for Q4 2025, up 23% quarter-over-quarter.
  • 12 funds opened new Acumen Pharmaceuticals positions in Q4 2025 and 8 closed out, a net change of +4 holders.
  • The largest Acumen Pharmaceuticals buyer in Q4 2025 was Susquehanna International Group, an estimated $315K added.
  • The largest Acumen Pharmaceuticals seller in Q4 2025 was Renaissance Technologies, an estimated $320K sold.

Based on aggregated 13F filings for Q4 2025.